Group 1: Institutional Research on Popular Companies - The top twenty companies with the highest number of institutional research visits in the past 30 days include Huaming Equipment, Changshu Bank, Guangdian Yuntong, Yunnan Baiyao, and BYD. In the last five days, the most visited companies were Mankalon, Zhou Dasheng, Stable Medical, Zhujiang Beer, and Shenghe Resources. Among the top twenty companies in the past 30 days, 11 companies had 10 or more rating agencies, including BYD, Huali Group, Weixing New Materials, Changshu Bank, and Weixing Co., Ltd. [2][11][12] - Companies such as BYD, Huali Group, Changshu Bank, Weixing Co., Ltd., Weichai Power, Yunnan Baiyao, Tuobang Co., Ltd., Huaming Equipment, and Zhongji United are expected to see significant growth in net profit attributable to shareholders in 2024 compared to 2023 [2][11][12]. Group 2: Shareholder Increase Activities - From May 5 to May 9, 2025, a total of 13 companies announced significant shareholder increases, with three companies having 10 or more rating agencies. The companies with an average proposed increase amount exceeding 1% of the latest market value include *ST Gengxing, Hainan Development, China Railway Industry, Huamao Technology, and Linglong Tire [3][14][15]. - From January 1 to May 11, 2025, 297 companies announced significant shareholder increases, with 203 having 10 or more rating agencies. Among these, 15 companies had an average proposed increase amount exceeding 1% of the latest market value, including Xinjie Energy, Sailun Tire, Rongsheng Petrochemical, Wanrun Co., Ltd., CNOOC Engineering, and Xin Fengming [5][16][17]. Group 3: Company Buyback Activities - From May 5 to May 9, 2025, a total of 312 companies announced buyback progress, with 84 companies having 10 or more rating agencies. Companies expected to have a buyback amount exceeding 1% of the market value on the announcement date include Pingmei Co., Ltd., Huafa Co., Ltd., Changhong Meiling, XGIMI Technology, and Xugong Machinery [4][19][20]. - From January 1 to May 11, 2025, 1,456 companies announced buyback progress, with 297 having 10 or more rating agencies. Among these, 82 companies had a buyback amount exceeding 1% of the market value on the announcement date, including Changhong Meiling, Qianwei Central Kitchen, Baolong Technology, Shantui Co., Ltd., Wanrun Co., Ltd., Midea Group, BOE A, and Goldwind Technology [6][22][23].

这张截图来自明讯创始人的朋友圈，我最开始于 3 月 20 日发布在我的公众号里。 关于初创公司 - 明讯科技，和投资机构 - 同创 wy 的纠纷，不知还有多少人不了解背景。 我当时发布的文章，除了这张截图外，还有来自鲸准 app 的，同创投资明讯的截图。除此之外，没有我的原创内容。 然后， 20 日下午，同创发出一则公告，称明讯创始人的指控严重不实，同时也要求各自媒体删除相关内容。 同时，创始人也删除了朋友圈的内容。于是，我也删了我的文章。 有小伙伴问我删掉的那篇是什么内容，为什么删掉，我在此做个补充解释。 关于这份纠纷，公众号"创投日报"于 3 月 22 日发布了对明讯创始人的专访，比较真实全面的还原了事件过程。 我在 3 月 31 日发布的《回购的真实模样》，也部分是在为这件事，为创始人发声。 在我眼里，大部分创始人在投资机构面前是相对弱势的一方，是信息不对称的一方， 而且，我曾按合伙人的指示，亲手在回购和落地等事项上，让初创企业元气大伤，让企业新一轮难以为继。 我的价值观让我不得不为创始人发声。如果我有偏颇，有说的不对的地方，我承认。我毕竟只是一个个人公众号。 然后，在《回购的真实模样》的评论里我有提到 ...

Core Viewpoint - The company held its 2024 annual performance online briefing, where it faced numerous investor questions but did not provide responses to most inquiries, indicating a lack of transparency or communication strategy during challenging times [1][2][3]. Financial Performance - In 2024, the company achieved a revenue of 3.03 billion yuan and a net profit of 1.96 billion yuan, reflecting a year-on-year growth of 5.5% and 5.3% respectively [16]. - The company reported a significant decline in revenue and profit in the fourth quarter of 2024, raising concerns among investors about future performance [2][3]. Market Strategy - The company is focusing on international expansion, with plans to leverage the acquisition of REGEN Biotech, Inc. to enhance its global presence [18]. - The company is committed to maintaining its core business and improving product offerings without diversifying into downstream operations [11][19]. Product Development - A new product, a medical-grade polyvinyl alcohol gel microsphere, has received regulatory approval and is expected to launch in 2025 [6][22]. - The company is in the process of developing several products, including botulinum toxin, which is currently in the registration phase [14][22]. Investor Relations - The company received 43 questions from investors during the briefing but only answered 27, resulting in a response rate of 62.79% [1]. - Investors expressed concerns about stock buybacks and the need for measures to boost confidence amid declining stock prices [2][4].